Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
Layoffs in the biopharma sector contunue into 2Q24. Bristol Myers Squibb in its 1Q results announced a Strategic Productivity ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
The layoffs first started last month, when Tesla began laying off what was said to be at the time 10 percent of the company’s ...
In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward: whether its recent purchases will pay off.
The move comes after the Elon Musk-led automaker disbanded its EV charging department following Tesla’s announcement last ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Chroma Medicine laid off an undisclosed number of employees ... Sandoz reached an agreement with Amgen to resolve all patent ...
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...